U.S. markets open in 1 hour 50 minutes

Arena Pharmaceuticals, Inc. (ARNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
63.07-1.23 (-1.91%)
At close: 4:00PM EDT

Arena Pharmaceuticals, Inc.

136 Heber Avenue
Park City, UT 84060
United States
858 453 7200
http://www.arenapharm.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees363

Key Executives

NameTitlePayExercisedYear Born
Mr. Amit D. Munshi M.B.A.Pres, CEO & Director1.22M14.78M1968
Mr. Vincent E. AurentzExec. VP & Chief Bus. Officer692.82k1.13M1968
Dr. Preston S. KlassenAdvisorN/AN/A1969
Mr. Robert LisickiExec. VP & Chief Commercial Officer686.63k671.85k1968
Ms. Laurie D. StelzerExec. VP & CFO630.76kN/A1968
Dr. Douglas A. BakanExec. VP of Technical OperationsN/AN/AN/A
Megan E. KnightDirector of Investor RelationsN/AN/AN/A
Ms. Joan SchmidtExec. VP, Gen. Counsel & Sec.624.61kN/A1964
Patrick MalloyVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Dr. Christopher H. CabellAdvisor687.1k4.36MN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.

Corporate Governance

Arena Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.